April 29, 2026 a 09:00 am
GILD: Analysts Ratings - Gilead Sciences, Inc.
Gilead Sciences, Inc., as a leading biopharmaceutical company, continues to draw attention from analysts due to its expansive portfolio in unmet medical need areas. Recent analysis reveals a varied range of sentiments with Buy and Hold recommendations being predominant. The company’s strong performance in the HIV/AIDS and liver disease segments, along with continued innovation in emerging medical sectors, underlines its robust market presence.
Historical Stock Grades
The following table illustrates the latest analyst ratings for Gilead Sciences, Inc. as of April 2026:
| Recommendation | Number of Ratings | Score Visualization |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 18 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- Over the past year, a notable shift is seen in recommendations, from "Strong Buy" to a more cautious "Buy" and "Hold" stance.
- The absence of "Sell" and "Strong Sell" recommendations suggests confidence in the stock's stability.
- Fluctuations in "Strong Buy" recommendations trend reflect dynamic market perception and valuation of Gilead's growth prospects.
Percentage Trends
- A gradual increase in "Hold" ratings over the months suggests a cautious outlook.
- "Strong Buy" ratings saw a marginal decline, reflecting a potential reassessment of growth expectations.
- "Buy" recommendations remain strong, indicating sustained confidence in the company's portfolio and future performance.
- From a percentage perspective, ratings transition could indicate growing market caution, with analysts recalibrating expectations as competition increases in specific drug markets.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-13 | Buy | Buy | Citigroup |
| 2026-04-10 | Overweight | Overweight | Morgan Stanley |
| 2026-02-23 | Buy | Buy | Needham |
| 2026-02-11 | Sector Perform | Sector Perform | RBC Capital |
| 2026-02-11 | Overweight | Overweight | Cantor Fitzgerald |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-08 | Buy | Hold | Truist Securities |
| 2025-07-25 | Buy | Hold | Needham |
| 2025-02-18 | Buy | Hold | Deutsche Bank |
| 2025-01-10 | Overweight | Equal Weight | Morgan Stanley |
| 2024-11-08 | Hold | Buy | Maxim Group |
Interpretation
The consistency in recommendation largely retaining a "Buy" and "Hold" suggests positive investor sentiment bolstered by Gilead's strategic market positions, despite market volatility. Analysts bear varied anticipations resulting in a more conservative evaluation, indicating enhanced risk assessment protocols due to emerging competitive landscapes and evolving market demands. The analyst community's current sentiment implies cautious optimism, with prevailing confidence in Gilead's expanding therapeutic offerings and market adaptability, albeit coupled with tempered growth expectations amid external market pressures.
Conclusion
Overall, Gilead Sciences remains a substantial player in the pharmaceutical industry, receiving commendable affirmation from analysts in both the "Buy" and "Hold" categories. Despite certain anticipated risks from rising competition, Gilead's continued product innovation across critical medical fronts provides a robust base for optimistic future performance. The gradual shift towards more conservative ratings underscores a market nuanced by risk considerations and strategic recalibrations. Looking forward, while the ratings hint at prudent growth strategies and risk alignments, potential investors should consider ongoing developments within Gilead's research and commercial outcomes.